Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide for T2D patients in China based on cost-utili...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Shanshan, Su, Xiaorong, Deng, Xun, Wang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220214/
https://www.ncbi.nlm.nih.gov/pubmed/34177604
http://dx.doi.org/10.3389/fphar.2021.701446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220214/
https://www.ncbi.nlm.nih.gov/pubmed/34177604
http://dx.doi.org/10.3389/fphar.2021.701446

Ejemplares similares